Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,667 across all filing types
Latest filing 2010-03-24 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Results from 12 Month Animal Hernia Trial 4 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement to the Australian Stock Exchange by bioMD Limited regarding the results of a 12-month pre-clinical animal trial for a hernia repair product. It details the trial design, observations, and conclusions about the product's performance compared to controls. The document is a public announcement of trial results and future plans for human clinical trials, not a financial report, regulatory filing, or management discussion. It does not contain financial statements, earnings data, or governance information. It is a corporate announcement about product development progress intended for investors and the market. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into other specific categories.
2010-03-24 English
Offer document despatch 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is an announcement to the Australian Stock Exchange regarding the despatch of an Entitlements Issue Offer Document for a non-renounceable rights issue to raise capital. It mentions the offer document was lodged previously with ASIC and ASX. The content focuses on informing shareholders about the rights issue offer document dispatch, which is a capital raising activity. The document length is short (1172 characters), and it is clearly an announcement rather than the offer document itself or a detailed financial report. Therefore, it fits best under Capital/Financing Update (CAP).
2010-03-16 English
Update on NAMSA biocompatibility testing 3 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is an announcement to the Australian Stock Exchange regarding interim results from biocompatibility testing of medical products by bioMD Limited. It includes detailed test results and conclusions from NAMSA testing but does not present comprehensive financial data, management discussion, or regulatory filings typical of annual or interim reports. The document is a corporate announcement updating shareholders and the market on product testing progress, not a financial report or regulatory filing. It is not a certification or voting result announcement. The content is focused on product testing updates, which fits best under a general regulatory announcement category rather than a financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (8881 characters) and content support this classification with high confidence.
2010-03-11 English
Interim results from Cardiocel clinical trial 4 pages ?Kb
Regulatory Filings
2010-03-03 English
Rights Issue Amended Timetable 1 page ?Kb
Capital/Financing Update Classification · 95% confidence The document is a short announcement to the Australian Stock Exchange regarding an amended timetable for a pro-rata non-renounceable rights issue. It contains no financial statements or detailed financial data, only dates and procedural information about the rights issue process. The document length is only 1570 characters, which is quite short and fits the pattern of an announcement rather than a full report. Therefore, it is best classified as a Capital/Financing Update (CAP) since it relates to a rights issue, which is a capital raising activity.
2010-03-02 English
Appendix 3B 8 pages ?Kb
Capital/Financing Update Classification · 100% confidence The document is titled 'APPENDIX 3B (AMENDED)' and is addressed as an announcement to the Australian Stock Exchange. It details a pro-rata non-renounceable issue of options, including the number of securities issued, terms of the options, issue price, purpose, dates related to the issue, underwriting fees, and quotation agreement. Appendix 3B is a standard form used in Australian stock exchange filings to announce new issues of securities and applications for quotation of additional securities. The document is a regulatory announcement about a capital raising event and the issuance of new options, not a full financial report or earnings release. It is not a report but an official announcement of a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (over 12,000 characters) and detailed content confirm it is not merely a brief notice or report publication announcement.
2010-03-01 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.